Western Research Park

Sernova’s Principal Investigator to Present Interim Data from the Company’s Ongoing Phase I/II Cell Pouch Clinical Trial at the 17th World Congress of the International Pancreas and Islet Transplant Association

LONDON, ONTARIO – June 27, 2019 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF), a clinical-stage regenerative medicine company is pleased to announce that Dr. Piotr Witkowski, Director of Pancreatic, and Islet Transplant Program at the University of Chicago, will present, in an oral podium session, early preliminary data and observations from Sernova’s ongoing clinical trial, entitled A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation, at the 17th World Congress of the International Pancreas and Islet Transplantation Association (IPITA) which is being held July 2 – 5, 2019 in Lyon, France.

Dr. Witkowski is scheduled to deliver his address during a symposium on islet transplantation on July 3, 2019 at 10:45 a.m. (CET) at Lyon’s Catholic University in the Amphitheater Merieux 1 & 2. Further details on the scientific program can be found on the conference website

About IPITA
The International Pancreas and Islet Transplantation Association aims to serve the pancreas and islet transplant scientific community in providing a forum for the open exchange of knowledge and expertise in order to facilitate the advancement of the clinical practice of pancreas and islet transplantation for the treatment of human diabetes.

About Sernova's Clinical Trial
Sernova is conducting a Phase I/II non-randomized, unblinded, single arm, company-sponsored trial, to assess the safety and tolerability of islet transplantation into the company’s patented Cell Pouch in diabetic subjects with hypoglycemia unawareness. The secondary objective is to assess efficacy through a series of defined measures.

Eligible subjects are implanted with Cell Pouches. Following development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression and a dose of purified islets, under strict release criteria, transplanted into the Cell Pouch.

A sentinel pouch is removed for an early assessment of the islet transplant. Subjects are followed for additional safety and efficacy measures for approximately six months. At this point, a decision will be made with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will be then further followed for one year to assess longer-term safety and efficacy. 
For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more information on enrollment and recruitment details please visit www.pwitkowski.org/sernova.
 
About Sernova Corp.
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.


For further information contact:

CANADA

Ray Matthews & Associates
Tel: (604) 818-7778
ray@raymatthews.ca 
www.raymatthews.ca  

Dominic Gray,
Corporate Communications
Tel: (519) 858-5126
dominic.gray@sernova.com 
www.sernova.com 

UNITED STATES

Danny Matthews
Solebury Trout
Tel: (646) 378-2928
dmatthews@soleburytrout.com 
www.soleburytrout.com